Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval…